Key facts
- It has raised $55.0M across 3 recorded rounds; the latest was Early Stage VC ($33.0M) in May 2024.
- Notable investors include Mana Ventures, Gaingels, Samsung NEXT Ventures, Breyer Capital, Emerson Collective — 19 tracked in total.
- Atropos Health has filed 3 Form Ds with the SEC since 2022, most recently May 2024 ($33.0M sold to 7 investors).
- Status: Privately Held (backing).
Leadership
- Andrew TuritzChief Financial Officer
- Cecily HarrisGeneral Counsel
- Cory WiegertChief Operating Officer
- Kevin SmithExecutive
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Atropos Health
Funding rounds
3 roundsAbout Atropos Health
Developer of a clinical analytics platform designed to transform health data into usable real-world evidence. The company's platform leverages electronic medical record data to derive digital evidence for individual patient outcomes with data-driven care, and expedites research that advances the field of medicine, enabling healthcare institutions to create value from previously siloed EMR data.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2020
- Employees
- 37
- Website
- atroposhealth.com/
- Ownership
- Privately Held (backing)
Atropos Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atropos Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atropos Health in its N-PORT filings yet. We sweep new filings monthly.